Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - ChronoScale Corp (0001549084) (Issuer)
4 - ChronoScale Corp (0001549084) (Issuer)
4 - ChronoScale Corp (0001549084) (Issuer)
DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN) ("ChronoScale" or the "Company"), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer. The appointments strengthen ChronoScale's executive leadership team as the Company expands its AI infrastructure platform and accelerates delivery of large-scale compute solutions for enterprises, hyperscalers, and AI innovators worldwide. "AI infrastructure is entering a new era where performance, efficiency, and execution matter more than ever," said Ce
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointment of Cenly Chen as Chief Executive Officer and a member of the Company's Board of Directors. Ms. Chen brings more than two decades of experience scaling enterprise infrastructure and high-performance computing platforms in global markets. She most recently served as Chief Growth Officer, Senior Vice President & Managing Director at Super Micro Computer, Inc. (NASDAQ:SMCI), where she led global growth initiatives across AI and enterprise infrastructure markets. "We believe the mar
SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the "Company") (NASDAQ:EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional and accredited investors for the purchase and sale of an aggregate of 5,852 shares of the Company's Series B Preferred Stock (the "Preferred Stock") and warrants (the "Warrants") to purchase up to an aggregate of 355,960 shares of common stock of the Company in a private placement transaction (the "Private Placement"). The shares of Preferred Stock will have a stated value of $1,000 per share and b
8-K - ChronoScale Corp (0001549084) (Filer)
8-K/A - ChronoScale Corp (0001549084) (Filer)
SCHEDULE 13D - ChronoScale Corp (0001549084) (Subject)
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into the NVIDIA Connect program, supporting Ekso's new strategic initiative to build a proprietary foundation model for human motion and to help develop and integrate related new artificial intelligence
SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter of 2025 after the close of trading on Monday, July 28, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at ww
SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its
DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN) ("ChronoScale" or the "Company"), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer. The appointments strengthen ChronoScale's executive leadership team as the Company expands its AI infrastructure platform and accelerates delivery of large-scale compute solutions for enterprises, hyperscalers, and AI innovators worldwide. "AI infrastructure is entering a new era where performance, efficiency, and execution matter more than ever," said Ce
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointment of Cenly Chen as Chief Executive Officer and a member of the Company's Board of Directors. Ms. Chen brings more than two decades of experience scaling enterprise infrastructure and high-performance computing platforms in global markets. She most recently served as Chief Growth Officer, Senior Vice President & Managing Director at Super Micro Computer, Inc. (NASDAQ:SMCI), where she led global growth initiatives across AI and enterprise infrastructure markets. "We believe the mar
Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic
SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)
SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)
SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)